Proud to be presenting our abstract 4716 An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL) at ASH 2019 between 6 and 8 PM tonight in Orlando.
ASH 2019: Proud to be presenting our abstract... - CLL Support
ASH 2019
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
5 Replies
•
Good work, Brian!
We are proud of you, too!
Our CLL specialist is at this conference as well.
Thanks for your dedication and hard work!!!
Thank you!!!!
Not what you're looking for?
You may also like...
Reporting from ASCO 2019 (yes ASCO, not ASH)
Hi,
With ASH looming, it’s about time I finish up my reporting from ASCO 2019, the other huge...
ASH 2019: U-MRD by subgroup (ibrutinib+venetoclax) CAPTIVATE trial
This is how we achieve personalized, precision medicine.
73% of patients achieved U-MRD4 in BM...
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista
Prof Nicole Lamanna - ASH 2019 - Maturing CLL clinical trial data
Dr. Nicole Lamanna, Associate...
ASH 2019: U-MRD kinetics in the CLL14 trial (V+O vs Chl+O)
In this trial, treatments were given for 12 months. Note the decreasing slope of the MRD levels...
ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
"Conclusion:
This study demonstrates that it is safe to administrate a single dose of Sativex to...
ASH 2012 Ibrutinib Press Conference
Jeff Sharman - ASH 2016 with Patient Power
Ibrutinnib cost in 2019
